| Biomarker ID | 542 |
| PMID | 20889560 |
| Year | 2010 |
| Biomarker | MMP-9 intensity |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased expression in Overall Mortality |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: 0.6 (95% CI: 0.45-0.8) |
| Effect on Pathways | Pathway Includes:- Syndecan 1 pathway,Gastrin pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,TWEAK signaling pathway, Endochondral ossification |
| Experiment | Overall Mortality Vs No Mortality |
| Type of Biomarker | Prognostic |
| Cohort | 278 with prostate cancer were chosen. At the end time, 210 patients were alive, 228 patients had no event with regard to disease-specific mortality, and 87 patients were without biochemical recurrence were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | This study stands in contrast to other studies, showing an association of MMP-9 expression with tumor progression in PCa |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MMP9 |